Table 3.
PsA resistance risk factors for clinical outcomes
| Citation, study design, location | N C/T | Patient/infection description | Analysis | Variable | Proportion of patients with either outcome with variable | p-value | |
|---|---|---|---|---|---|---|---|
|
Rodriguez-Nunez et al. 2019 [28] Retrospective, multicenter International |
90 | Drug-resistant PsA RTIs (76.7% XDR; 23.3% MDR) | Univariate regression | XDR PsA infection |
Survivors (N = 65) |
Non-survivors (N = 25) |
.308 |
|
73.8% (48/65) |
84.0% (21/25) |
||||||
|
Diaz-Cañestro et al. 2018 [30] Prospective, single center Spain |
58 | PsA (86.2% XDR; 10.3% MDR) infections, including RTIs (60.3%), UTIs (17.2%), and IAIs (6.9%) | Univariate regression |
Clinical cure (N = 35) |
Clinical failure (N = 21) | ||
| Resistance profile | .045 | ||||||
| XDR PsA infection |
82.8% (29/35) |
100.0% (21/21) |
|||||
| MDR PsA infection |
17.1% (6/35) |
0.0% (0/21) |
|||||
p-value < 0.05 indicates a significant difference are shown in bold
C/T: Ceftolozane/tazobactam; IAI: Intra-abdominal infection; MDR: Multidrug-resistant; PsA: Pseudomonas aeruginosa; RTI: Respiratory tract infection; UTI: Urinary tract infection; XDR: Extensively-drug-resistant